Cargando…
Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias
BACKGROUND: The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485978/ https://www.ncbi.nlm.nih.gov/pubmed/37684653 http://dx.doi.org/10.1186/s13195-023-01300-y |
_version_ | 1785102902175465472 |
---|---|
author | Bentivenga, Giuseppe Mario Baiardi, Simone Mastrangelo, Andrea Zenesini, Corrado Mammana, Angela Polischi, Barbara Capellari, Sabina Parchi, Piero |
author_facet | Bentivenga, Giuseppe Mario Baiardi, Simone Mastrangelo, Andrea Zenesini, Corrado Mammana, Angela Polischi, Barbara Capellari, Sabina Parchi, Piero |
author_sort | Bentivenga, Giuseppe Mario |
collection | PubMed |
description | BACKGROUND: The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia. METHODS: In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14–3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses. RESULTS: CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240–1250 vs. 115, 95% CI 78–157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411–1473 vs. 390, 95% CI 260–766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873–0.931) exceeded that of 14–3-3 (AUC 0.853, 95% CI 0.816–0.889), t-tau (AUC 0.878, 95% CI 0.845–0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851–0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626–0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593–0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729–0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40–2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21–2.93). CONCLUSIONS: In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14–3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14–3-3 and NfL, respectively. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01300-y. |
format | Online Article Text |
id | pubmed-10485978 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104859782023-09-09 Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias Bentivenga, Giuseppe Mario Baiardi, Simone Mastrangelo, Andrea Zenesini, Corrado Mammana, Angela Polischi, Barbara Capellari, Sabina Parchi, Piero Alzheimers Res Ther Research BACKGROUND: The levels of synaptic markers synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) have been shown to increase early in the cerebrospinal fluid (CSF) of patients with Creutzfeldt-Jakob disease (CJD) and to have prognostic potential. However, no validation studies assessed these biomarkers' diagnostic and prognostic value in a large clinical setting cohort of rapidly progressive dementia. METHODS: In this retrospective study, using commercially available immunoassays, we measured the levels of SNAP-25, Ng, 14–3-3, total-tau (t-tau), neurofilament light chain (NfL), and phospho-tau181 (p-tau) in CSF samples from consecutive patients with CJD (n = 220) or non-prion rapidly progressive dementia (np-RPD) (n = 213). We evaluated and compared the diagnostic accuracy of each CSF biomarker and biomarker combination by receiver operating characteristics curve (ROC) analyses, studied SNAP-25 and Ng CSF concentrations distribution across CJD subtypes, and estimated their association with survival using multivariable Cox regression analyses. RESULTS: CSF SNAP-25 and Ng levels were higher in CJD than in np-RPD (SNAP-25: 582, 95% CI 240–1250 vs. 115, 95% CI 78–157 pg/ml, p < 0.0001; Ng: 841, 95% CI 411–1473 vs. 390, 95% CI 260–766 pg/ml, p < 0.001). SNAP-25 diagnostic accuracy (AUC 0.902, 95% CI 0.873–0.931) exceeded that of 14–3-3 (AUC 0.853, 95% CI 0.816–0.889), t-tau (AUC 0.878, 95% CI 0.845–0.901), and the t-tau/p-tau ratio (AUC 0.884, 95% CI 0.851–0.916). In contrast, Ng performed worse (AUC 0.697, 95% CI 0.626–0.767) than all other surrogate biomarkers, except for NfL (AUC 0.649, 95% CI 0.593–0.705). SNAP-25 maintained a relatively high diagnostic value even for atypical CJD subtypes (AUC 0.792, 95% CI 0.729–0.854). In Cox regression analyses, SNAP-25 levels were significantly associated with survival in CJD (hazard ratio [HR] 1.71 95% CI 1.40–2.09). Conversely, Ng was associated with survival only in the most rapidly progressive CJD subtypes (sCJD MM(V)1 and gCJD M1) (HR 1.81 95% CI 1.21–2.93). CONCLUSIONS: In the clinical setting, CSF SNAP-25 is a viable alternative to t-tau, 14–3-3, and the t-tau/p-tau ratio in discriminating the CJD subtypes from other RPDs. Additionally, SNAP-25 and, to a lesser extent, Ng predict survival in CJD, showing prognostic power in the range of CSF t-tau/14–3-3 and NfL, respectively. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-023-01300-y. BioMed Central 2023-09-08 /pmc/articles/PMC10485978/ /pubmed/37684653 http://dx.doi.org/10.1186/s13195-023-01300-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bentivenga, Giuseppe Mario Baiardi, Simone Mastrangelo, Andrea Zenesini, Corrado Mammana, Angela Polischi, Barbara Capellari, Sabina Parchi, Piero Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias |
title | Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias |
title_full | Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias |
title_fullStr | Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias |
title_full_unstemmed | Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias |
title_short | Diagnostic and prognostic value of cerebrospinal fluid SNAP-25 and neurogranin in Creutzfeldt-Jakob disease in a clinical setting cohort of rapidly progressive dementias |
title_sort | diagnostic and prognostic value of cerebrospinal fluid snap-25 and neurogranin in creutzfeldt-jakob disease in a clinical setting cohort of rapidly progressive dementias |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485978/ https://www.ncbi.nlm.nih.gov/pubmed/37684653 http://dx.doi.org/10.1186/s13195-023-01300-y |
work_keys_str_mv | AT bentivengagiuseppemario diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT baiardisimone diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT mastrangeloandrea diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT zenesinicorrado diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT mammanaangela diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT polischibarbara diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT capellarisabina diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias AT parchipiero diagnosticandprognosticvalueofcerebrospinalfluidsnap25andneurograninincreutzfeldtjakobdiseaseinaclinicalsettingcohortofrapidlyprogressivedementias |